

January 5, 2004

**LISTING OF THE CLAIMS AS AMENDED**

Please cancel claims 91-95 and 147 without prejudice or admission, and amend claims 115-117 and 123 as follows:

Claims 1-68: (Canceled)

Claim 69: (Previously presented) An antibody that is capable of binding human CTLA4 with a binding affinity of about  $10^8 \text{ M}^{-1}$  or greater, which antibody comprises a heavy chain variable region of a human  $V_H$  3-30.3 or  $V_H$  3-33 gene, and wherein the antibody inhibits binding of the human CTLA4 to B7-1 or to B7-2.

Claim 70: (Previously presented) An antibody according to claim 69, wherein said antibody binds human CTLA4 with a binding affinity of about  $10^9 \text{ M}^{-1}$  or greater.

Claim 71: (Previously presented) An antibody according to claim 69, wherein said antibody does not bind CTLA4 from mouse.

Claim 72: (Previously presented) An antibody according to claim 69, wherein said antibody binds CTLA4 from cynomolgus monkey.

Claim 73: (Previously presented) An antibody according to claim 69, which antibody reduces binding of human CTLA4 to B7-1 by at least 50% when the concentration of antibody is at least about 1  $\mu\text{g/mL}$ .

Claim 74: (Previously presented) An antibody according to claim 69, which antibody reduces binding of human CTLA4 to B7-2 by at least 50% when the concentration of antibody is at least about 1  $\mu\text{g/mL}$ .

**January 5, 2004**

Claim 75: (Previously presented) An antibody according to claim 69 wherein the heavy chain variable region comprises CDR amino acid sequences set forth in SEQ ID NOS:27, 32 and 37.

Claim 76: (Previously presented) An antibody according to claim 69, wherein the heavy chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NOS:17, 19 and 23.

Claim 77: (Previously presented) An antibody according to claim 69, which antibody further comprises a light chain variable region of a human V<sub>K</sub> A-27 or V<sub>K</sub> L-15 gene.

Claim 78: (Previously presented) An antibody according to claim 77, wherein the light chain variable region comprises CDR amino acid sequences set forth in SEQ ID NOS:24, 29 and 35.

Claim 79: (Previously presented) An antibody according to claim 77, wherein the light chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NOS:7, 9 and 13.

Claim 80: (Previously presented) An antibody that is capable of binding human CTLA4 with a binding affinity of about  $10^8 \text{ M}^{-1}$  or greater,

which antibody comprises a light chain variable region of a human V<sub>K</sub> A-27 or V<sub>K</sub> L-15 gene, and

wherein the antibody inhibits binding of the human CTLA4 to B7-1 or to B7-2.

Claim 81: (Previously presented) An antibody according to claim 80, wherein said antibody binds human CTLA4 with a binding affinity of about  $10^9 \text{ M}^{-1}$  or greater.

Claim 82: (Previously presented) An antibody according to claim 80, wherein said antibody does not bind CTLA4 from mouse.

**January 5, 2004**

Claim 83: (Previously presented) An antibody according to claim 80, wherein said antibody binds CTLA4 from cynomolgus monkey.

Claim 84: (Previously presented) An antibody according to claim 80, which antibody reduces binding of human CTLA4 to B7-1 by at least 50% when the concentration of antibody is at least about 1  $\mu$ g/mL.

Claim 85: (Previously presented) An antibody according to claim 80, which antibody reduces binding of human CTLA4 to B7-2 by at least 50% when the concentration of antibody is at least about 1  $\mu$ g/mL.

Claim 86: (Previously presented) An antibody according to claim 80, wherein the light chain variable region comprises CDR amino acid sequences set forth in SEQ ID NOS:24, 29 and 35.

Claim 87: (Previously presented) An antibody according to claim 80, wherein the light chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NOS:7, 9 and 13.

Claim 88: (Previously presented) An antibody according to claim 80, which antibody further comprises a heavy chain variable region of a human V<sub>H</sub> 3-30.3 or V<sub>H</sub> 3-33 gene.

Claim 89: (Previously presented) An antibody according to claim 88, wherein the heavy chain variable region comprises CDR amino acid sequences set forth in SEQ ID NOS:27, 32 and 37.

Claim 90: (Previously presented) An antibody according to claim 88, wherein the heavy chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NOS:17, 19 and 23.

Claims 91 – 114: (Canceled)

Claim 115: (Currently amended) An antibody comprising:

- (a) a heavy chain variable amino acid sequence having the amino acid sequence set forth in SEQ ID NOS NO:19; and
- (b) a light chain variable amino acid sequence having the amino acid sequence set forth in SEQ ID NO:9,

wherein the antibody is capable of binding CTLA-4.

Claim 116: (Currently amended) An antibody comprising:

- (a) a heavy chain variable amino acid sequence having the amino acid sequence set forth in SEQ ID NOS NO:17; and
- (b) a light chain variable amino acid sequence having the amino acid sequence set forth in SEQ ID NO:7,

wherein the antibody is capable of binding CTLA4.

Claim 117: (Currently amended) An antibody comprising:

- (a) a heavy chain variable amino acid sequence having the amino acid sequence set forth in SEQ ID NOS NO:23; and
- (b) a light chain variable amino acid sequence having the amino acid sequence set forth in SEQ ID NO:13,

wherein the antibody is capable of binding CTLA4.

Claim 118: (Previously presented) An antibody capable of binding CTLA4, which antibody comprises:

- (a) a heavy chain variable region having CDR sequences set forth in SEQ ID NOS:27, 32 and 37; and
- (b) a light chain variable region having CDR sequences set forth in SEQ ID NOS:24, 29 and 35.

Claim 119: (Previously presented) An antibody capable of binding CTLA4, which antibody comprises:

- (a) a heavy chain variable region having CDR sequences set forth in SEQ ID NOS:27, 33 and 37; and
- (b) a light chain variable region having CDR sequences set forth in SEQ ID NOS:25, 30 and 35.

Claim 120: (Previously presented) An antibody capable of binding CTLA4, which antibody comprises:

- (a) a heavy chain variable region having CDR sequences set forth in SEQ ID NOS:28, 34 and 38; and
- (b) a light chain variable region having CDR sequences set forth in SEQ ID NOS:26, 31 and 36.

Claim 121: (Previously presented) An antibody capable of binding human CTLA4, which antibody comprises:

- (a) a heavy chain variable region of a human V<sub>H</sub> 3-30.3 gene; and
- (b) a light chain variable region of a human V<sub>K</sub> A-27 gene.

Claim 122: (Previously presented) An antibody according to claim 121, wherein the antibody is capable of binding human CTLA4 with a binding affinity of about  $10^8 \text{ M}^{-1}$  or greater.

Claim 123: (Currently amended) An antibody according to claim 121, wherein the antibody is capable of binding human CTLA4 with a binding affinity of about  $[10^8] \text{ } 10^9 \text{ M}^{-1}$  or greater.

Claim 124: (Previously presented) An antibody according to claim 121, wherein the antibody inhibits binding of the human CTLA4 to B7-1 or to B7-2.

**January 5, 2004**

Claim 125: (Previously presented) An antibody according to claim 124, wherein the antibody reduces binding of the human CTLA4 to B7-1 by at least 50% when the concentration of antibody is at least 1  $\mu\text{g}/\text{mL}$ .

Claim 126: (Previously presented) An antibody according to claim 124, wherein the antibody reduces binding of the human CTLA4 to B7-2 by at least 50% when the concentration of antibody is at least 1  $\mu\text{g}/\text{mL}$ .

Claim 127: (Previously presented) An antibody according to claim 121, wherein the antibody does not cross-react with non-lymphoid tissue.

Claim 128: (Previously presented) An antibody according to claim 121, wherein the antibody does not bind CTLA4 from mouse.

Claim 129: (Previously presented) An antibody according to claim 121, wherein the antibody is capable of binding CTLA4 from cynomolgus monkey.

Claim 130: (Previously presented) An antibody capable of binding human CTLA4, which antibody comprises:

- (a) a heavy chain variable region of a human  $V_H$  3-33 gene; and
- (b) a light chain variable region of a human  $V_K$  L-15 gene.

Claim 131: (Previously presented) An antibody according to claim 130, wherein the antibody is capable of binding human CTLA4 with a binding affinity of about  $10^8 \text{ M}^{-1}$  or greater.

Claim 132: (Previously presented) An antibody according to claim 130, wherein the antibody is capable of binding human CTLA4 with a binding affinity of about  $10^9 \text{ M}^{-1}$  or greater.

**January 5, 2004**

Claim 133: (Previously presented) An antibody according to claim 130, wherein the antibody inhibits binding of the human CTLA4 to B7-1 or to B7-2.

Claim 134: (Previously presented) An antibody according to claim 133, wherein the antibody reduces binding of the human CTLA4 to B7-1 by at least 50% when the concentration of antibody is at least 1  $\mu$ g/mL.

Claim 135: (Previously presented) An antibody according to claim 133, wherein the antibody reduces binding of the human CTLA4 to B7-2 by at least 50% when the concentration of antibody is at least 1  $\mu$ g/mL.

Claim 136: (Previously presented) An antibody according to claim 130, wherein the antibody does not cross-react with non-lymphoid tissue.

Claim 137: (Previously presented) An antibody according to claim 130, wherein the antibody does not bind CTLA4 from mouse.

Claim 138: (Previously presented) An antibody according to claim 130, wherein the antibody is capable of binding CTLA4 from cynomolgus monkey.

Claim 139: (Previously presented) An antibody according to claim 69 wherein the heavy chain variable region comprises CDR amino acid sequences set forth in SEQ ID NOS:27, 33 and 37.

Claim 140: (Previously presented) An antibody according to claim 69 wherein the heavy chain variable region comprises CDR amino acid sequences set forth in SEQ ID NOS:28, 34 and 38.

**January 5, 2004**

Claim 141: (Previously presented) An antibody according to claim 77, wherein the light chain variable region comprises CDR amino acid sequences set forth in SEQ ID NOS:25, 30 and 35.

Claim 142: (Previously presented) An antibody according to claim 77, wherein the light chain variable region comprises CDR amino acid sequences set forth in SEQ ID NOS:26, 31, and 36.

Claim 143: (Previously presented) An antibody according to claim 80, wherein the light chain variable region comprises CDR amino acid sequences set forth in SEQ ID NOS:25, 30 and 35.

Claim 144: (Previously presented) An antibody according to claim 80, wherein the light chain variable region comprises CDR amino acid sequences set forth in SEQ ID NOS:26, 31, and 36.

Claim 145: (Previously presented) An antibody according to claim 88, wherein the heavy chain variable region comprises CDR amino acid sequences set forth in SEQ ID NOS:27, 33 and 37.

Claim 146: (Previously presented) An antibody according to claim 88, wherein the heavy chain variable region comprises CDR amino acid sequences set forth in SEQ ID NOS:28, 34 and 38.

Claim 147: (Canceled)

\* \* \* \* \*